1. Liu, Jialiang, Ren, Guangli, Li, Kangshuai, Zhang, Zongli, Xu, Yunfei. 2021. The Smad4-MYO18A-PP1A complex regulates β-catenin phosphorylation and pemigatinib resistance by inhibiting PAK1 in cholangiocarcinoma. In Cell death and differentiation, 29, 818-831. doi:10.1038/s41418-021-00897-7. https://pubmed.ncbi.nlm.nih.gov/34799729/
2. Horsthemke, Markus, Arnaud, Charles-Adrien, Hanley, Peter J. 2024. Are the class 18 myosins Myo18A and Myo18B specialist sarcomeric proteins? In Frontiers in physiology, 15, 1401717. doi:10.3389/fphys.2024.1401717. https://pubmed.ncbi.nlm.nih.gov/38784114/
3. Cao, Can, Zhang, Chao, Sun, Ying, Mu, Zhen, Shen, Qin. 2021. Myosin18B predicts favorable prognosis of cutaneous squamous-cell carcinoma. In Genes & genomics, 43, 371-378. doi:10.1007/s13258-021-01037-8. https://pubmed.ncbi.nlm.nih.gov/33555505/
4. Yang, Linlin, Carrillo, Marykate, Wu, Yuchieh M, Christensen, Neil D, Chroneos, Zissis C. 2015. SP-R210 (Myo18A) Isoforms as Intrinsic Modulators of Macrophage Priming and Activation. In PloS one, 10, e0126576. doi:10.1371/journal.pone.0126576. https://pubmed.ncbi.nlm.nih.gov/25965346/